Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Bethesda, Maryland
Taste and smell thresholds and forced scaling levels the impairment in taste and olfaction that result.
were studied in 29 patients with Sjogren's syndrome
and in 10 patients with various diseases of the parotid Patients and Methods
PATIENTS
glands, with and without xerostomia and rhinitis sicca.
Patients with xerostomia and rhinitis sicca Twenty-nine female patients with Sjogren's syndrome
due to Sjogren's syndrome or other causes had were studied at the Clinical Center, National Institutes
of Health, over a period of 4 years.
significant decreases in taste and smell acuity. The diagnosis in each patient was made when the
Cyclophosphamide or X-ray treatment improved taste or clinical history and physical examination were consistent
smell function if the xerostomia or rhinitis sicca with the disease and with the demonstration of ophthal-
concomitantly improved. These studies suggest that mologic and oral abnormalities. Ophthalmological ab-
saliva and nasal mucus are important in maintaining normalities included decreased production of tears
(measured by Schirmer's test), corneal and conjunctival
normal taste and smell acuity through their effects on
erosions (detected by rose-bengal staining), and filamen-
taste bud and olfactory epithelium function. tary keratitis (observed on slit-lamp examination). Ab-
normalities of salivary gland function included measure-
ment of decreased parotid salivary flow rate, decreased
uptake concentration and excretion of technetium-99
(demonstrated by salivary scintigraphy (5)), an ab-
S J O G R E N ' S SYNDROME is defined as the symptom normal secretory sialogram, and the finding of lympho-
cytic infiltrates and acinar destruction on examination
complex of xerostomia, xerophthalmia, and a con- of labial biopsy specimens (6).
nective tissue disorder, which is rheumatoid arthritis To establish the diagnosis of' Sjogren's syndrome,
in approximately half the patients ( 1 , 2 ) . A few objective evidence of involvement of two of the three
patients may have another associated connective tis- major symptom areas (that is, abnormalities of eye, oral
sue disorder such as systemic lupus erythematosus cavity, or connective tissue) was required. Eleven of the
or scleroderma. Hypergammaglobulinemia, rheuma- 29 patients studied had associated rheumatoid arthritis,
2 had associated systemic lupus erythematosus, 2 had
toid factor, antisalivary duct antibodies, and other accompanying lymphoma, and the rest had the sicca
serological signs of autoimmune phenomena occur syndrome alone. The 29 patients were examined at NIH
frequently ( 2 ) . Destruction of the salivary glands by from 1 to 30 years after the onset of their symptoms;
lymphocytic infiltration leads to insufficient produc- the mean time after onset was 7 years.
tion of saliva, resulting in xerostomia. A similar Ten additional patients with bilateral disease of the
parotid glands were also studied. Five of these patients
process involving lacrimal and nasal mucous secret- had clinical complaints of oral and nasal dryness, and
ing glands results in xerophthalmia and rhinitis sicca, the parotid salivary flow rates were decreased below
respectively. In some patients lymphocytic infiltration normal in each patient. However, there was insufficient
may involve other organs such as lung or kidney objective evidence to establish the diagnosis of Sjogren's
and present a histological appearance of lymphoma syndrome. One patient had excessive fat deposits in the
parotid glands (7), one had bilateral stenosis of Sten-
or pseudolymphoma (3, 4 ) . sen's ducts of unknown cause, and three had no obvious
In this paper we describe, in detail, the clinico- explanations for their complaints. The other five patients
pathologic changes that occur in the oral, nasal, had normal parotid gland salivary flow rates, although
and pharyngeal areas during this illness and report some complained of mouth dryness. Three patients had
excessive fat deposits in the parotid glands, bilaterally
• From the National Heart and Lung Institute, National Institute of (7); one had Mikulicz's syndrome; and one had parotid
Arthritis and Metabolic Diseases, and National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda, Md. disease of unknown cause.
Annals of Internal Medicine 76:375-383, 1972 375
* Numerator of fracton is median detection threshold; denominator of fraction is median recognition threshold.
t oosignifies inability to detect or recognize an absolute or neat substance; P signifies ability to recognize an absolute or neat substance; K
signifies a factor of 1000.
Xerostomia Rhinitis Number of NaCl Sucrose HC1 Urea Pyridine Nitrobenzene ThiopheneJ.
Sicca Patients
< mmoles /liter > — moles/liter - >
+ + 5 90/90 75/75 15/150 900/1500 10-710- 1 1 3
IO- - /! P/P
5 30/30 60/60 6/6 120/120 io- 6 3 /io- 2 io-6-3/io-8-8 io- 6 - 6 /io- 8 -
* Numerator of fraction is median detection threshold; denominator of fraction is median recognition threshold,
t P signifies ability to detect or recognize an absolute or neat substance.
patient's taste buds suggested that marked degenera- associated with their illness: pulmonary lymphoma
tive changes had occurred. (Patient T.J.), pseudolymphoma of the parotid
Smell Thresholds: Median detection and recog- glands (Patient F.E.), renal insufficiency secondary
nition thresholds for smell in the 29 patients in- to lymphoid infiltration (Patient R.G.), and active
dicated that thresholds for each vapor were elevated rheumatoid arthritis (Patient H.K.). A fifth patient
above normal. All patients (29 of 29) had elevated (M.R.) received extensive radiotherapy to the head
detection and recognition thresholds for pyridine; and neck for pseudolymphoma of the parotid glands.
24 ( 8 3 % ) had elevated detection thresholds for Three of these patients, T.J., F.E., and M.R., noted
nitrobenzene, and 22 ( 7 6 % ) had elevated recogni- subjective remissions of oral and lacrimal dryness;
tion thresholds. Twenty-eight patients had elevated salivary flow rates in all three returned to or toward
detection thresholds for thiophene, and 26 had ele- normal. Only Patient T.J. noted a remission of her
vated recognition thresholds. nasal dryness. Two other patients, R.G. and H.K.,
Table 2 compares the median detection and rec- noted no subjective change in oral, lacrimal, or nasal
ognition thresholds for taste and smell in five patients dryness, and there was no change in salivary flow rate
with parotid gland disorders and xerostomia and when it was measured.
rhinitis sicca with similar thresholds in five patients Taste and smell thresholds were measured in each
with parotid gland disorders without xerostomia patient before and after therapy with cyclophospha-
or rhinitis sicca. Taste thresholds were elevated above mide (Table 3 ) . No change in taste or smell thresh-
normal for all of the eight qualities in patients with olds was noted in Patients R.G. or H.K., in whom
xerostomia; similarly, smell thresholds were elevated no change in oral or nasal dryness occurred. Of
above normal. However, taste thresholds were within those three patients who noted a return of saliva,
normal limits for each quality in the patients with- taste thresholds and olfactory thresholds returned to
out xerostomia, and smell thresholds were similarly normal in the patient (T.J.) who noted a remission of
within normal limits for each vapor in patients with- her rhinitis sicca.
out rhinitis sicca. An attempt was made to correlate abnormalities
Changes After Therapy: Four patients were treated of taste and smell thresholds with abnormalities
with cyclophosphamide (Cytoxan®) for problems observed on examination of Up biopsy specimens,
Table 3. Taste and Smell Thresholds in 5 Patients with Sjogren's Syndrome Before and After Cyclophosphamide or X-ray Treatment*
Table 3. (Continued)
Response t Treated
Xerostomia Rhinitis Other NaCl Sucrose HC1 Urea Pyridine Nitrobenzene Thiophene
Sicca
< mmoles/liter • < moles/liter — •
9 4
+ + 12/60 60/60 3/6 120/120 10- /10- IO-7IO-4 10-710-*
+ + 30/60 12/12 0.5/3 120/120 10"V2 10-710- 1 10-7P
+ + 60/60 30/30 3/3 120/150 10-710- 2 10-710-2 10-7P
+ 300/800 300/300 60/90 2K/2K 10-710- 1 10-710-2 P/P
1
150/300 90/90 15/60 800/1K 10-710- 1 10-710- P/P
Median 30/60 30/30 3/3 120/120
% + = improvement; — = no improvement.
§ = retested 2 years after therapy.